Last reviewed · How we verify
NCT05337163
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
trial testing Diagnostic Test: Sputum DNA methylation analysis in Lung Cancer in 1,564 participants. Completed in 5 March 2025.
18 February 2025
Quick facts
| Lead sponsor | Creative Biosciences (Guangzhou) Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,564 |
| Start date | 25 February 2022 |
| Primary completion | 18 February 2025 |
| Estimated completion | 5 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Diagnostic Test: Sputum DNA methylation analysis
- chest CT or pathological examination
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →
- Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
- Squamous Cell Carcinoma — all drugs for Squamous Cell Carcinoma →
Sponsor
Creative Biosciences (Guangzhou) Co., Ltd.
Who can join
Eligibility, any sex, with Lung Cancer or Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method (includes chest CT examination or pathological examination).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review.
Wei Y, Wang L, Jin Z, Jia Q, et al · · 2024 · cited 14× · PMID 38601447 · DOI 10.21037/tlcr-24-127
Verify or expand the search:
- PubMed search for NCT05337163
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Creative Biosciences (Guangzhou) Co., Ltd. trials
Trials by the same sponsor.
- NCT05374369 — Retrospective Analysis of Colorectal Cancer Screening Results · completed
- NCT05337189 — A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China · recruiting
- NCT04722055 — A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05337163 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Creative Biosciences (Guangzhou) Co., Ltd.
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05337163.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing